Source 1primary paper2025MED
Toolkit/druggable ligand-dependent IL-21 secretion system
druggable ligand-dependent IL-21 secretion system
Also known as: ligand-responsive IL-21 secretion system
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
we developed a druggable ligand-dependent IL-21 secretion system using destabilization domains (DDs).
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Published Workflows
Objective: Engineer a drug-controllable IL-21 secretion system in T cells to achieve precise, reversible, and tunable cytokine release for adoptive cell therapy applications.
Why it works: The paper links drug-responsive destabilization domains to controllable IL-21 secretion and uses structural analysis to identify fusion orientations that better preserve IL-21 receptor interaction before evaluating functional effects in primary T cells.
destabilization-domain-mediated ligand control of IL-21 secretionpreservation or improvement of IL-21 receptor binding through fusion orientationprotein fusion engineeringstructural analysisprimary T-cell functional testing
Stages
- 1.Destabilization-domain construct comparison for ligand-responsive IL-21 secretion(broad_screen)
This stage compares candidate destabilization domains to find constructs that support controllable IL-21 secretion, with ER50 highlighted for more sustained regulation.
Selection: Identify destabilization domains that facilitate ligand-responsive IL-21 secretion and compare regulation durability.
- 2.Structural analysis of fusion orientation and IL-21 receptor binding(secondary_characterization)
This stage evaluates whether the engineered fusion architecture preserves or improves IL-21 receptor interaction, which is important for downstream biological activity.
Selection: Assess how fusion orientation affects IL-21 receptor binding.
- 3.Primary T-cell functional evaluation(confirmatory_validation)
This stage confirms that the controllable IL-21 secretion system retains a therapeutically relevant functional effect in primary T cells.
Selection: Test whether engineered IL-21 secretion produces a desirable T-cell state relevant to adoptive therapy.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Mechanisms
destabilization-domain-mediated control of protein abundanceligand-dependent protein stabilizationreversible tuning of cytokine secretionTechniques
Structural CharacterizationTarget processes
recombinationInput: Chemical
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
In primary T cells, IL-21 secretion promoted T stem-like cell differentiation and enhanced persistence relevant to adoptive cell therapy.
In primary T cells, IL-21 secretion promoted T stem-like (Tscm) cell differentiation, enhancing persistence for adoptive cell therapy.
ER50 and DHFR both enabled ligand-responsive IL-21 secretion, and ER50 provided more sustained regulation than DHFR.
ER50 and DHFR facilitated ligand-responsive IL-21 secretion, with ER50 providing the most sustained regulation.
A destabilization-domain-based ligand-dependent IL-21 secretion system was developed to enable precise control of cytokine release.
To enable precise control, we developed a druggable ligand-dependent IL-21 secretion system using destabilization domains (DDs).
N-terminal fusion improved IL-21 receptor binding whereas C-terminal fusion weakened interactions.
Structural analysis revealed that N-terminal fusion improved IL-21 receptor binding, while C-terminal fusion weakened interactions.
The ligand-responsive IL-21 secretion system enables reversible, tunable cytokine control and is presented as a safer, more flexible approach for engineered T cell therapies.
This system enables reversible, tunable cytokine control, offering a safer and more flexible approach for engineered T cell therapies.
Approval Evidence
1 source4 linked approval claimsfirst-pass slug druggable-ligand-dependent-il-21-secretion-system
we developed a druggable ligand-dependent IL-21 secretion system using destabilization domains (DDs).
Source:
cell state effectsupports
In primary T cells, IL-21 secretion promoted T stem-like cell differentiation and enhanced persistence relevant to adoptive cell therapy.
In primary T cells, IL-21 secretion promoted T stem-like (Tscm) cell differentiation, enhancing persistence for adoptive cell therapy.
Source:
engineering outcomesupports
A destabilization-domain-based ligand-dependent IL-21 secretion system was developed to enable precise control of cytokine release.
To enable precise control, we developed a druggable ligand-dependent IL-21 secretion system using destabilization domains (DDs).
Source:
structure functionsupports
N-terminal fusion improved IL-21 receptor binding whereas C-terminal fusion weakened interactions.
Structural analysis revealed that N-terminal fusion improved IL-21 receptor binding, while C-terminal fusion weakened interactions.
Source:
translational positioningsupports
The ligand-responsive IL-21 secretion system enables reversible, tunable cytokine control and is presented as a safer, more flexible approach for engineered T cell therapies.
This system enables reversible, tunable cytokine control, offering a safer and more flexible approach for engineered T cell therapies.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.